-
Capital, M&A & Industry Strategy2 days agoAnthropic’s historic IPO; Akeso’s big clinical showing
Anthropic is setting the stage for the largest IPO in history and Akeso has been touting its latest positive results for its buzzy bispecific.
-
AI, Machine Learning & Computational Biology1 month agoRoche’s AI lab; Biohaven’s pivotal pause
Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven
-
AI, Machine Learning & Computational Biology1 month agoBasecamp raises $140M before the clinic; J&J and Compass’ potential rivalry
Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Another big AI haul Investors are still...
-
Manufacturing, Supply Chain & Infrastructure2 months agoMerck builds around Keytruda; prediction markets raise new risks
Merck pursues new cancer combinations, prediction markets put pharma’s confidential information in focus and personalized cancer vaccines confront manufacturing hurdles.
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoGilead’s growing HIV franchise; cell therapy licensing deals plummet
The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
Helixgate Featured2 days ago
Widespread atropine use fails to sway FDA advisors on Sydnexis data
Helixgate Featured2 days ago
At least 11 PDUFAs on FDA’s November docket
Helixgate Featured2 days ago
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Uncategorized7 months ago
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized6 months ago
